Larvol Delta - Safety-and-Efficacy-of-Ruxolitinib-in-Patients-With-HNSCC-and-High-NLR-Treated-With-Pembrolizumab--The-Phase-2-InflammaSTOP-Trial

Jakafi (ruxolitinib) - Incyte

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT07840456

Sep 26, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next